Stephen Silberstein

All papers authored by Stephen Silberstein

This paper was not found in any repository, but could be made available legally by the author.

2022 Todd J. Schwedt, Cristina Tassorelli

, Stephen D. Silberstein

, Faisal Mohammad Amin

, Christina L. Szperka

, Tobias Kurth

, Patricia Pozo-Rosich, Richard B. Lipton, David W. Dodick, Messoud Ashina, Hans-Christoph Diener

, Gisela M. Terwindt

Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1^st edition

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Thaiza Agostini Córdoba de Lima

, Mario Fernando Prieto Peres

, Stephen D. Silberstein

Applicability of DSM-V substance use disorder (SUD) criteria in medication overuse headache (MOH)

Upload

2021 Hsiangkuo Yuan

, John G. Curran, Scott W. Keith, Mary M. Hopkins, Stephen D. Silberstein

Intravenous ibuprofen for acute treatment of migraine: A double‐blind, randomized, placebo‐controlled pilot study

Upload

Todd J. Schwedt, Richard B. Lipton, Jessica Ailani, Stephen D. Silberstein

, Cristina Tassorelli

, Hua Guo, Kaifeng Lu, Brett Dabruzzo, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M. Trugman

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

Upload

Vimala N. Bharadwaj

, Frank Porreca

, Robert P. Cowan

, Shashidhar Kori, Stephen D. Silberstein

, David C. Yeomans

A new hypothesis linking oxytocin to menstrual migraine

Upload

Cristina Tassorelli

, Hans-Christoph Diener

, Stephen D. Silberstein

, David W. Dodick, Peter J. Goadsby

, Rigmor H. Jensen, Delphine Magis

, Patricia Pozo-Rosich, Hsiangkuo Yuan, Daniele Martinelli

, Thomas van den Hoek, Marie Deen

, Messoud Ashina

, Gisela M. Terwindt

Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

Upload

Susan Hutchinson, Stephen D. Silberstein

, Andrew M. Blumenfeld, Richard B. Lipton, Kaifeng Lu, Sung Yun Yu, Lawrence Severt

Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II

Upload

This paper is made freely available by the publisher.

Stephen D. Silberstein

, Joshua M. Cohen, Ronghua Yang, Sanjay K. Gandhi, Evelyn Du, Adelene E. Jann, Michael J. Marmura

Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

Download from doi.org

2020 Richard B. Lipton, Stewart J. Tepper, Stephen D. Silberstein

, David Kudrow, Messoud Ashina

, Uwe Reuter, David W. Dodick, Feng Zhang, Gregory A. Rippon, Sunfa Cheng, Daniel D. Mikol

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

Download from journals.sagepub.com

Stephen Silberstein

, Merle Diamond, Nada A. Hindiyeh, David M. Biondi, Roger Cady, Joe Hirman, Brent Allan, Susan Pederson, Barbara Schaeffler, Jeff Smith

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

Download from doi.org

Stephen D. Silberstein

, Joshua M. Cohen, Michael J. Seminerio, Ronghua Yang, Sait Ashina, Zaza Katsarava

The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study

Download from doi.org

Claire Ej Ceriani, Stephen D. Silberstein

Headache and rhinosinusitis: A review

Upload

Hans-Christoph Diener, Thomas C. van den Hoek, Diener Hc, Cristina Tassorelli, Dodick Dw, David W. Dodick, Silberstein Sd, Stephan D. Silberstein

, Richard B. Lipton, Lipton Rb, Messoud Ashina

, Werner J. Becker, Becker Wj, Michel D. Ferrari, Ferrari Md and 11 other authors

Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults

Download from journals.sagepub.com

Stephen D. Silberstein

, Hsiangkuo Yuan

, Umer Najib, Jessica Ailani, Andreia Lopes de Morais, Paul G. Mathew, Eric Liebler, Cristina Tassorelli

, Hans-Christoph Diener

Non-invasive vagus nerve stimulation for primary headache: A clinical update

Upload

Steven C. Marcus, Anand R. Shewale, Stephen D. Silberstein

, Richard B. Lipton, William B. Young, Hema N. Viswanathan, Jalpa A. Doshi

Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response

Upload

Stewart J. Tepper, Messoud Ashina

, Uwe Reuter, Jan Lewis Brandes, David Doležil, Stephen D. Silberstein

, Paul Winner, Feng Zhang, Sunfa Cheng, Daniel D. Mikol

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

Download from journals.sagepub.com

Alicia Alpuente

, Cristina Tassorelli

, Hans-Christoph Diener, Stephen D. Silberstein

, Patricia Pozo-Rosich

Have the IHS Guidelines for controlled trials of acute treatment of migraine attacks been followed? Laying the ground for the 4th edition

Upload

David W. Dodick, Anand S. Shewale

, Richard B. Lipton, Seth J. Baum, Steven C. Marcus, Stephen D. Silberstein

, Jelena M. Pavlovic, Nathan L. Bennett, William B. Young, Hema N. Viswanathan, Jalpa A. Doshi, Howard Weintraub

Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data

Upload

David Kudrow, Sagar Munjal, Leah Bensimon, Tasneem Lokhandwala

, Binglin Yue, Anna D’Souza Coutinho, Stephen D. Silberstein

Treatment patterns of patients diagnosed with major headache disorders: A retrospective claims analysis

Upload

2019 Messoud Ashina

, David Kudrow, Uwe Reuter, David Dolezil, Stephen Silberstein

, Stewart J. Tepper, Fei Xue, Hernan Picard, Feng Zhang, Andrea Wang, Yanchen Zhou, Frank Hong, Jan Klatt, Daniel D. Mikol

Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions

Download from journals.sagepub.com

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Stephen Silberstein